ERBB2 and neoplasm: In vivo, the therapeutic efficacy of MVs targeted to HER2/neu and EpCAM by designing ankyrin repeat proteins (DARPins), was confirmed in an orthotopic ovarian carcinoma model revealing an effective reduction of tumor mass [48].